PDUFA Hearing Will Address NDA Approval Slowdown Claims
This article was originally published in The Tan Sheet
Executive Summary
Drug approval times will be one topic of interest at the House Energy & Commerce/Health Subcommittee's May 3 hearing kicking off the user fee reauthorization process, Commerce Committee Majority Counsel Brent Del Monte told the Food & Drug Law Institute conference in Washington, D.C. April 18.